Numerous studies provide evidence that Src inhibitors are effective in reducing proliferation and invasion of prostate cancer cell lines in vitro and demonstrate favorable antitumor activity in vivo using prostate cancer xenografts (38–40). Here, SRC is linked to prostate carcinoma.